Schedule of DCTD Presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
DCTD-supported research will be presented at the ASCO Annual Meeting from May 29 - June 2, 2026. The following tables include the oral and poster sessions containing DCTD staff speakers and co-authors.
Oral Presentations
| Title | Link Date/Time |
|---|---|
| Narrowing the Gap on Clinical Trial Enrollment Among Adolescents and Young Adults with Sarcoma NCI Speaker: Nita L. Seibel, MD | Education Session May 30/1:15-1:27 PM CDT |
| DART (NCI/SWOG S1609): Comprehensive Results from Dual Checkpoint Inhibition with CTLA-1 and PD-1 Blockade in Rare Cancers | Oral Abstract Session May 31/8:24-8:36 AM CDT |
Poster Presentations
OAOral Abstract Session; PPoster Presentation; PDPoster Discussion Session
| Title/DCTD Presenter (If Applicable) | Link/ Abstract # |
|---|---|
| Final analysis of KOMET (NCT04924608), a phase 3 study of selumetinib in adults with NF1-PN Alice P. Chen, MD | P3110 |
| ETCTN 10302: A randomized phase 2 trial of radium-223 dichloride in combination with paclitaxel in patients with bone metastatic breast cancer | P3096 |
| Topoisomerase 1 and DNA damage: Pharmacodynamic responses and mechanism of trastuzumab deruxtecan in HER2-expressing advanced solid tumors | P3092 |
| Comprehensive genomic profiling of matched ctDNA and tissue from patients with four common cancers enrolled to the NCI-MATCH trial | P3045 |
| HER2-independent antitumor and pharmacodynamic responses to trastuzumab deruxtecan in patient with advanced solid tumors Sarah Shin, MD, MPH | P3031 |
| Differences in central versus local lab PD-L1 classification in the ALCHEMIST Alliance A151216 non-small cell lung cancer (NSCLC) study | P8057 |
| Randomized phase 3 study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST) | OA8000 |
| Adjuvant erlotinib versus observation after complete resection of EGFR-mutant NSCLC: Final overall survival results of Alliance A081105 | OA8001 |
| MATRiX: A randomized phase 2 trial of tuvusertib (ATR inhibitor) with or without avelumab in advanced anti-PD(L)-1 refractory Merkel cell carcinoma | PLBA9514 |
| A phase 1 study pomalidomide and nivolumab (Pom/Nivo) in patients with virus-associated malignancies with and without HIV | PD2663 |
| Final results and preliminary correlative analysis of a phase 1 study of anetumab ravtansine in combination with checkpoint inhibitors and gemcitabine in mesothelin-positive advanced pancreatic adenocarcinoma (NCI10208) | P4205 |